Zinger Key Points
- TC Biopharm shares are trading lower by 62% during Friday's session.
- The company announced the transition from Nasdaq to OTC markets.
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.
TC Biopharm PLC – ADR TCBP shares are trading lower by 62% to 58 cents during Friday’s session after the company announced the transition from Nasdaq to OTC markets.
What To Know: TC BioPharm a clinical-stage biotech firm, announced that Nasdaq has decided to delist its securities for failing to meet the $1.00 minimum bid price requirement under Rule 5550(a)(2).
The company received notice of this decision on Thursday. TC BioPharm, which focuses on allogeneic gamma-delta T-cell therapies for cancer and other diseases, is now working on an appeal to Nasdaq in an effort to regain compliance.
Read Also: ‘Monster Equity Inflows Say No One Really Believes Trade War,’ Bank Of America’s Hartnett Says
According to data from Benzinga Pro, has a 52-week high of $523.20 and a 52-week low of $0.54.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
